Trials / Completed
CompletedNCT00228605
Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain
An Open-Label 12 Month Study to Evaluate the Safety, Tolerability and Efficacy of OraVescent Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Noncancer Pain
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 500 (planned)
- Sponsor
- Cephalon · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl for the potential treatment of breakthrough pain episodes in patients who have chronic noncancer pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OraVescent Fentanyl |
Timeline
- Start date
- 2005-03-01
- Completion
- 2007-05-01
- First posted
- 2005-09-29
- Last updated
- 2014-05-09
Locations
38 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00228605. Inclusion in this directory is not an endorsement.